Point-of-Delivery Drug Reconstitution Systems to 2017: Markets, Strategies and Prospects
|出版商||Greystone Research Associates||商品編碼||111920|
|針點注射給藥的藥物的復原·溶解系統:市場·策略·展望 Point-of-Delivery Drug Reconstitution Systems to 2017: Markets, Strategies and Prospects|
|出版日期: 2013年01月02日||內容資訊: 英文||
Greystone Research Associates is pleased to announce the publication of a new market study. Point-of-Delivery Drug Reconstitution Systems to 2017 is a comprehensive evaluation and analysis of the technology, devices and participants behind the innovative approaches that address the growing need for packaging and delivering lyophilized drugs for injection.
The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for reconstituting lyophilized drugs at the point of use. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
The inherent instability of biological drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed - a distribution strategy referred to as the ‘Cold Chain'. Alternatively, proteins can be formulated as powders (lyophilization). Lyophilized proteins must be reconstituted prior to injection. Lyophilized drugs are sold with reconstitution vial systems, or packaged in special injection devices (e.g., pens, needle-free injectors, two-part syringes) that allow reconstitution to take place in the device prior to injection. As biological drugs continue to grow in terms of therapeutics and total prescriptions, the impact of specialty devices will increase.